the coding sequence of RUVBL2 in 10 sequenced cases. Silencing RUVBL2 in HuH7 HCC cells reduced cell growth (p< 0.001) and increased apoptosis as shown by DNA fragmentation (p<0.001) and caspase 3 activity (p< 0.005). This was associated with an increased expression of several pro-apoptotic genes, and with an increased conformational activation of Bak-1 and Bax. On the other hand, HuH7 cells with overexpression of RUVBL2 grew better in soft agar (p< 0.03), had an increased resistance to C2 ceramide-induced apoptosis (p< 0.001) and gave rise to significantly larger tumors when injected to immunodeficient Rag2/γc mice (p = 0.016). In conclusion, RUVBL2 is overexpressed in a large majority of HCC. RUVBL2 overexpression enhances tumorigenicity and RUVBL2 is required for tumor cell viability.
These results argue for a major role of RUVBL2 in liver carcinogenesis.
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer. Despite the discovery of several carcinogenetic pathways, the mechanisms of liver carcinogenesis are still unclear (1) . It is also apparent that the underlying mechanisms may be different according to the etiology of the HCC (2, 3). Due to its high incidence in occidental countries, hepatitis C is responsible for a strong increase in HCC incidence. As several other groups (4, 5) , we have recently applied proteomics technology to discover new markers or targets in HCV-related HCC. This was done using 2D-electrophoresis and mass spectrometry and led to the discovery of many regulated proteins (6) including the recently uncovered protein RUVBL2, also known as TIP49b (7), TIP48 (8) , Reptin52 (9), Rvb2 (10), TAP54β (11) , ECP-51 (12) and TIH2p (13) . RUVBL2 contains the Walker A and Walker B motifs which are found in proteins that bind and hydrolyze ATP (14) . RUVBL2 also has limited homology to the bacterial RuvB ATP-dependent DNA helicase. Human RUVBL2 has indeed been shown to have ATPase activity (7, 11) whereas its DNA helicase activity has been disputed (7, 11) .
RUVBL2 is found in several nuclear high molecular weight chromatin-remodeling complexes (10, 11) . Recently, it was found that RUVBL2 was able to interact with β-catenin resulting in altered TCF/LEF-mediated transcription (9, 15). RUVBL2 also interacts with a domain of cmyc required for oncogenic transformation (8) and its expression is controlled by c-myc itself (8, 16) . Given that β-catenin and c-myc are two key actors of liver carcinogenesis, our study was designed to assess the role of RUVBL2 in liver carcinogenesis.
Experimental procedures

Liver samples
Samples came from resected or explanted livers with HCC of patients treated in Bordeaux from 1992 to 2005. Fragments of fresh tumoral and non-tumoral liver tissues (taken at a HAL author manuscript inserm-00173425, version 1 distance of at least 2 cm from the tumor) were immediately snap-frozen in liquid nitrogen and stored at -80°C. DNA and RNA were extracted as described (17). The proteomic study included 4 male patients (mean age 77, range 72-82) with HCC developed on chronic viral hepatitis C (stage F3 for 3 patients and F2 for one patient, according to Metavir classification (18) ). In addition, HCC samples from 96 patients related to various etiologies were used for quantitative RT-PCR analysis and immunohistochemistry. The main clinical and pathological characteristics are indicated in Table 1 . Six normal liver samples taken at distance from benign liver tumors were used as controls in quantitative RT-PCR and immunohistochemistry. Survival analysis included 45 patients treated with a complete tumor resection before 2002; patients treated with liver transplantation, incomplete resection, or deceased in the post-operative period were excluded.
Proteomic analysis
Four tumoral samples were compared to matched non-tumor samples using 2D electrophoresis as previously described in detail (6).
Real-time RT-PCR
Liver samples. One µg of total RNA was reverse transcribed using the High capacity Archive kit and random hexamers (Applied Biosystems) and 5 µl of cDNA corresponding to 10 ng of reverse transcribed RNA were analyzed by TaqMan PCR analysis, in duplicate, using the ABI PRISM ® 7900HT System (Applied Biosystems). Pre-developed sequence detection reagents specific for human RUVBL2 gene (Applied Biosystems) were used as described (17) using the 2 -∆∆CT method (19) . Briefly, gene expression results were first normalized to internal control ribosomal 18S. Then, results in HCC samples were expressed as a ratio relatively to the mean expression level in non-tumor samples. We also measured the mRNA level of expression for HAL author manuscript inserm-00173425, version 1 c-myc, GLUL (encoding glutamine synthase) and GPR49 (encoding an orphan nuclear receptor), two well known β-catenin target genes, as previously described (20). Finally, mutations in the CTNNB1 gene coding for β-catenin were searched as described (2 We also measured the percentage of cells expressing the proliferation antigen Ki67 (24) .
Briefly, cells were fixed with 0.4 % paraformalehyde, permeabilized with 0.02 % saponin, then incubated with a FITC-labeled Ki67 antibody (Dako) and analyzed by flow cytometry.
Anchorage-independent growth was assayed as follows. Flag-RUVBL2 expressing cells or control cells (10,000) were suspended in DMEM containing 10 % FCS and 0.2% agar (overlay) on top of an agar underlay (DMEM/10% FCS/0.5% agar) in a 60 mm diameter dish.
Cells were fed twice a week with 2 ml of overlay medium, and the area of colonies was measured after 2 weeks using Image J software (http://rsb.info.nih.gov/ij/). Thirty different fields (5X) were scored. The experiments were done in triplicate.
Assay for cell viability
Cells were seeded at a density of 6,000/well in 96w plates. After 7h, they were treated with the indicated agonists for 17h. Cell viability was assessed by incubating with DMEM containing 1 mg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) during 2 hours at 37°C as described (25). The linearity of the assay over the range of cell densities was checked in preliminary experiments.
Apoptosis
Cells were fixed using PFA 4% in PBS at 4°C during 10 min, then permeabilized with 0.5 % Triton X-100. They were stained with DAPI (Sigma, 0.5 µg/ml) together with a rabbit antihuman active caspase 3 antibody (R&D systems, 0.25 µg/ml). After washing, cells were incubated with goat anti-rabbit Alexa 488 (Molecular Probes) and examined under a Zeiss
Axioplan microscope.
The extent of DNA fragmentation was quantified with flow cytometry as described (26) .
Briefly, trypsinized cells were resuspended in 0.1% sodium citrate containing 0.1% Triton X-HAL author manuscript inserm-00173425, version 1 100, 50 µg/ml propidium iodide and 100 µg/ml RNAse. Cell DNA content was measured using a FACScalibur (BD Biosciences, San Jose, CA, USA).
We also quantified caspase 3 activity using a colorimetric kit from Chemicon (Temecula, California), according to instructions from the supplier. Briefly, cleared cell extracts were incubated with the caspase 3 substrate and optical density was read at 405 nm in a Dynatech microplate reader (MTX Lab Systems, Inc., Vienna, VA).
Finally, we assessed Bak-1 and Bax activation using antibodies (Bak-1 : AM03, Calbiochem, VWR International, Fontenay-sous-Bois, France ; Bax : 6A7 BD Pharmingen, Le Pont de Claix, France) that recognizes the N-terminus of the proteins made accessible following the conformational changes upon activation. This was done using flow cytometry as described by others (27, 28) . corporation, Texas). Age of patients and diameter of tumors were partitioned using median.
Survival analyses were performed using Cox model to fit maximum-likelihood proportional hazards models using STATA software.
Results
RUVBL2 expression in HCC
Proteome analysis was performed using 2DE gel electrophoresis comparing 4 HCC related to HCV infection with their matched non-tumor tissues. One of the 850 protein spots detected was increased in all 4 cases of HCC with a mean tumor/non tumor ratio of 4.1 (range 2.8-6.9) (Fig. 1A) . It was identified as RUVBL2, based on the detection of two peptides (GLGLDDALEPR and LLIVSTTPYSEK) and detailed MS/MS analysis as previously described (6) . Overexpression of RUVBL2 was confirmed by western blot in these 4 cases (Fig. 1B) .
The cellular localization of RUVBL2 was assessed by immunohistochemistry in 20 samples of HCC from various etiologies and in the corresponding non tumoral livers, as well as in 4
cases of histologically normal livers. In normal liver, RUVBL2 expression was found in a variable fraction of hepatocytes, where it was faint and restricted to the nucleus; in addition, RUVBL2 staining was intense in bile duct cells where it was found in the nucleus and cytoplasm, and was also observed in some lymphocytes, either sinusoidal or portal ( Fig. 2A) .
The same staining pattern, in terms of distribution and intensity, was seen in all samples of peri-tumoral livers, whether cirrhotic or not ( Fig. 2C and 2F ). In sharp contrast, RUVBL2 was overexpressed in all analyzed HCC (Fig. 2C) , where in addition it showed a definite cytoplasmic staining that varied from faint to intense ( Fig. 2D-E ); in addition, nuclear staining of tumor cells was in most cases stronger than that of peri-tumoral hepatocytes ( Fig. 2D-E ). It should be noted however that the staining pattern was often heterogeneous within a given HAL author manuscript inserm-00173425, version 1 tumor (Fig. 2C) . In order to search for detailed clinico-pathological correlations, we measured RUVBL2 mRNA expression in a larger series of 96 well-annotated HCC related to various risk factors. We first confirmed in this series the increased expression of RUVBL2 transcripts in 72/96 HCC, ranging from 1.5 to 6.6 when compared with non-tumor liver tissues that ranged from 0.42 to 1.5 (p= 0.002, Fig. 3A ). RUVBL2 expression was significantly lower in HBV related HCC (Fig. 3B) whereas it was significantly higher in poorly differentiated tumors proportionally to the Edmondson grade (Fig. 3C) . In contrast, the other clinical and pathological characteristics mentioned in Table 1 were not significantly associated to RUVBL2 expression level. Using a Cox model analysis without partition, we showed a significant relationship between a high level of RUVBL2 in tumors and shorter overall survival of patients following surgery (p= 0.02; relative risk 1.4, standard error 0.2, CI 95%
1.05-1.85). In contrast, we did not find a difference of RUVBL2 expression in β-cateninactivated HCC when compared to CTNNB1 non-mutated HCC (Fig. 3D) . Accordingly, in the 96 HCC samples, we did not observe any correlation between the expression level of RUVBL2 and of β-catenin target genes (GLUL and GPR49, data not shown). In addition, cmyc transcript levels were measured in a subset of 42 patients and no correlation was found with RUVBL2 levels (r 2 = 0.01, p = 0.5, not shown).
Finally, the whole coding sequence of RUVBL2 was PCR-amplified in 10 HCC samples and no mutation leading to a change in amino-acid sequence was identified (not shown).
Thus, because RUVBL2 over-expression was found in the vast majority of HCC and was related to the aggressiveness of tumors, we explored the role of RUVBL2 in tumorigenesis by modulating its expression in the HCC cell line HuH7. 4A, the two targeting siRNAs led to a large decrease in RUVBL2 protein expression that reached more than 90% with siR1 and close to 80% with siR2. In both cases, the decrease was stable for at least 6 days.
We next evaluated the effect of RUVBL2 down expression on cell growth. The mean decrease with siR1 was 41.0 ± 4.4 % (n = 3, p < 0.04). Similarly, the percentage of cells positive for Ki67 was significantly decreased by both siR1 and with siR2 (Fig. 4C ).
In parallel, we observed that down regulation of RUVBL2 expression was associated with a high number of cells floating in the supernatant (not shown), suggesting that the cells may undergo apoptosis. This was confirmed by staining nuclear DNA with DAPI showing characteristic pictures of fragmented nuclei in RUVBL2 siRNA-transfected cells (Fig. 4E) , as compared to scrambled (Fig. 4D) . Simultaneous staining of the cells with an antibody specific for activated caspase 3 demonstrated that many cells transfected with RUVBL2 siRNAs showed an activation of this apoptotic pathway (compare Fig. 4G and 4F ). DNA fragmentation was quantified with flow cytometry that showed a significantly higher percentage of fragmented DNA at Day 6 post-transfection in cells transfected with siR1 or siR2 than in scrambled-transfected cells (ANOVA, p< 0.001; Fig 4J) . Similarly, quantification of caspase 3 activity with a colorimetric assay showed a significantly increased activity with both siR1 and siR2, as shown on Fig. 4K (ANOVA, p< 0.005).
In order to gain insight into the mechanisms of apoptosis, we measured the activation of the pro-apoptotic Bcl-2 family members Bax and Bak-1. These 2 proteins undergo a conformational activation that can be evidenced using conformation-sensitive antibodies in Bcl-xS at Day 4. There was also a trend towards an increase for Bax and PUMA, whereas no changes were seen for the anti-apoptotic gene Bcl-xL (Fig. 5C-D) .
Up-regulation of RUVBL2 expression promotes in vitro anchorage-independent cell growth and in vivo tumorigenesis
Here, Flag-tagged RUVBL2 was overexpressed under the control of the MND promoter in a lentiviral vector. Flag-tagged RUVBL2 could be easily detected and discriminated from endogenous RUVBL2 on Western blots due to its slower gel mobility. The factor of overexpression of RUVBL2 protein, assessed by making the sum of the intensities of the endogenous and the Flag-tagged RUVBL2 bands, was of only 1.2 in 2 independent
transductions. This was due at least in part to a decrease in endogenous RUVBL2 levels in Flag-RUVBL2-infected cells (Fig. 6A) . Several preliminary experiments allowed us to check that Flag-tagged RUVBL2 behaved similarly as endogenous RUVBL2 : western blot of HAL author manuscript inserm-00173425, version 1 nuclear and cytosolic extracts showed that both forms segregated alike in these 2 compartments; immunoprecipitation of Flag-tagged RUVBL2 pulled down expected partners (RUVBL1 and β-catenin (9)) indicating that the tagged protein was correctly incorporated into supra-molecular complexes (data not shown).
The growth rate on plastic of Flag-RUVBL2-expressing cells was compared to that of control EGFP-transfected cells. No differences in cell numbers were seen after 1, 2 or 3 days in serum concentrations ranging from 0.5 to 10% (data not shown). However, when anchorageindependent growth was measured in a soft agar assay, we found a large difference in the growth ability of Flag-RUVBL2-expressing cells, as shown by a significant increase in the surface of the colonies (Fig. 6B , p< 0.03, Kruskal-Wallis).
In subsequent experiments HuH7 cells were challenged with an apoptotic stimulus, C2
ceramide (30), and cell survival was assessed with the MTT assay. At every concentration of C2 ceramide tested, cells expressing Flag-RUVBL2 were slightly less susceptible to cell death than control cells. The difference was statistically significant except for the highest concentration of C2 ceramide when most cells were dead (Fig. 6C) . Furthermore, when the extent of DNA fragmentation, as an evidence for apoptosis, was examined, cells expressing Flag-RUVBL2 exhibited a significant protection over a range of C2 ceramide concentrations, as compared with control cells (Fig. 6D) . The fractional reduction in apoptosis as compared to control cells was 27.2 ± 6.0%, 19.3 ± 8.5% and 28.7 ± 3.3% at 20, 40 and 60 µM C2 ceramide, respectively. (Fig. 6F) . This also showed the persistent decrease in endogenous RUVBL2.
Discussion
Here, we show that RUVBL2 is up-regulated in a majority of HCCs. This over-expression is significantly associated with the differentiation grade of the tumors and RUVBL2 overexpression can be considered as a marker of poor prognosis. Moreover, our results strongly suggest that RUVBL2, a protein with no specific function yet ascribed in human, may play an essential role in liver carcinogenesis. To our knowledge, our findings are the first to report the deregulation of RUVBL2 expression in cancer. Our immunohistochemical data indicate that hepatocyte RUVBL2 expression appear increased in every HCC studied, although to a various extent. It is likely that tumor/non tumor ratios obtained with RT-PCR are artefactually low because of the high-level expression of RUVBL2 seen in the ductular proliferation of the non tumoral, cirrhotic livers (Fig. 2F ).
Cells where RUVBL2 was down-regulated showed a decreased proliferation rate, concomitant with a strong induction of apoptosis, as evidenced by the occurrence of DNA fragmentation and increased caspase 3 activity. In addition to HuH7, we observed a similar phenotype in 2 other HCC cell lines, Hep3B and FOCUS (not shown). Thus, RUVBL2 deficiency leads to liver cancer cell growth arrest and to apoptosis. RUVBL2 was previously shown to be also required for growth and survival of yeast (7, 31, 32) . Our data have shed some light on the mechanisms of apoptosis induced by RUVBL2 deficiency. We show that Their activation leads to the permeabilization of the outer membrane of mitochondria, resulting in cytochrome c release and caspase activation. In addition to protein activation, we also found that Bak-1 and Bax transcripts were upregulated, together with those of Bid, a BH3-only protein involved in Bak-1 and Bax activation (34, 35) , whereas interestingly, BclxL levels did not increase. These changes were seen as early as Day 3, well before the occurrence of cell death, suggesting that they may play a causal role. We thus propose that apoptosis induced by RUVBL2 depletion is linked to the activation of pro-apoptotic Bcl-2 family members. Such a mechanism could be amplified because of the transcriptional upregulation of these proteins. Whether the related genes are direct targets of RUVBL2 remains to be determined.
We then transduced cells with a lentiviral construct driving the expression of Flag-RUVBL2.
This led to only a modest increase in total expression of RUVBL2 which was not the consequence of a low level of transduction or of insufficient promoter activity, since RUVBL2 mRNA levels were 7.5 ± 2. RUVBL2 is known to physically interact with β-catenin (9). Several publications have shown that RUVBL2 behaved as an antagonist of the transcriptional activity of the β-catenin-TCF/LEF complex (9, 15). Since β-catenin is considered an oncogene in HCC, these results appear counter-intuitive. However, recently, RUVBL2 was also found to be required for the repressing effect of β-catenin on the transcription of the anti-metastatic gene KAI-1 (36) , that is frequently down-regulated in HCC (37) . In our study of a large number of HCC samples, there were however no correlations between the level of expression of RUVBL2 and of β−catenin target genes. It is thus likely that additional mechanisms, independent of β-catenin, may also explain the oncogenic properties of RUVBL2. Indeed, RUVBL2 has been found in supra-molecular complexes that do not include β-catenin (11), and β-catenin-independent functions of RUVBL2 have already been identified (15) . It is also noteworthy that RUVBL2
is required for the viability of yeast (7, 31, 32) , an organism devoid of β-catenin. In this context, one of the salient findings of this study was that in addition to its overexpression in HCC, RUVBL2 was also found in the cytoplasm of HCC cells. This suggests that RUVBL2 serves specific cancer-related functions in the cytoplasm of tumor cells.
We have thus identified a new protein up-regulated in HCC. In vitro and in vivo results suggest that RUVBL2 could play an important role in liver carcinogenesis. Since mutations in the ATPase domains of RUVBL2 abolish its biological activity (7, 31, 32) , targeting of its activity with specific inhibitors may offer a new therapeutic avenue in cancer management. 
Tumors characteristics
Diameter (mean ± SD ) 7.1 ± 5 cm
Intact capsule 16%
Satellite nodule 41%
Edmondson grade III or IV 57%
Microscopic vascular embolus 36%
CTNNB1 mutations 35%
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